rspНаучно-практическая ревматологияRheumatology Science and Practice1995-44841995-4492IMA-PRESS, LLC10.47360/1995-4484-2020-708-715rsp-2972Research ArticleПРОГРЕСС В РЕВМАТОЛОГИИ В XXI ВЕКЕPROGRESS IN RHEUMATOLOGY IN THE XXI CENTURYПрямые оральные антикоагулянты при антифосфолипидном синдромеDirect-acting oral anticoagulants in antiphospholipid syndromehttps://orcid.org/0000-0003-3552-2522РешетнякТ. М.ReshetnyakT. M.

Решетняк Татьяна Магомедалиевна – доктор медицинских наук, профессор, заведующая лабораторией сосудистой ревматологии.

115522, Москва, Каширское шоссе, 34А; 125993, Москва, ул. Баррикадная, 2/1, стр. 1

115522, Moscow, Kashirskoye Highway, 34A; 125993, Moscow, Barrikadnaya str., 2/1, building 1

t_reshet-nyak@yahoo.comhttps://orcid.org/0000-0001-6685-7670НурбаеваК. С.NurbaevaK. S.

Нурбаева Камила Сериковна - ординатор 2 года.

115522, Москва, Каширское шоссе, 34А

115522, Moscow, Kashirskoye Highway, 34A

ФГБНУ Научно-исследовательский институт ревматологии им. В.А. Насоновой; ФГБОУ ДПО Российская медицинская академия непрерывного профессионального образования Минздрава РоссииРоссияV.A. Nasonova Research Institute of Rheumatology; Russian Medical Academy of Continuous Professional Education of the Ministry of Healthcare of the Russian FederationRussian FederationФГБНУ Научно-исследовательский институт ревматологии им. В.А. НасоновойРоссияV.A. Nasonova Research Institute of RheumatologyRussian Federation202014012021586708715Copyright © Решетняк Т.М., Нурбаева К.С., 20212021Решетняк Т.М., Нурбаева К.С.Reshetnyak T.M., Nurbaeva K.S.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://rsp.mediar-press.net/rsp/article/view/2972

Антифосфолипидный синдром — приобретенная аутоиммунная тромбофилия, характеризующаяся развитием рецидивирующих тромбозов сосудов любого калибра и типа или акушерской патологией и обязательным выявлением стойко позитивных антифосфолипидных антител. Основным препаратам в курации больных с антифосфолипидным синдромом является варфарин. Роль прямых оральных антикоагулянтов в терапии антифосфолипидного синдрома остается противоречивой. В статье рассмотрены современные данные о месте прямых оральных антикоагулянтов в лечении антифосфолипидного синдрома.

Antiphospholipid syndrome is an acquired autoimmune thrombophilia characterized by the development of recurrent vascular thrombosis of any caliber and type or obstetric pathology and the mandatory identification of persistently positive antiphospholipid antibodies. The main drug in the treatment of patients with antiphospholipid syndrome is warfarin. The role of direct-acting oral anticoagulants in the treatment of antiphospholipid syndrome remains controversial. The article discusses modern data on the place of direct-acting oral anticoagulants in the treatment of antiphospholipid syndrome.

антифосфолипидный синдромпрямые оральные антикоагулянтыантифосфолипидные антителатромбозантикоагулянтыantiphospholipid syndromedirect-acting oral anticoagulantsantiphospholipid antibodiesthrombosisanticoagulantsReferencesНасонов ЕЛ. Антифосфолипидный синдром. М.: Изд-во «Литтера»; 2004:454.Nasonov EL. Antiphospholipid syndrome. Moscow: Littera Publishing House; 2004:454. (In Russ.).Решетняк ТМ. Антифосфолипидный синдром: диагностика и клинические проявления (лекция). Научно-практическая ревматология. 2014;52(1):56-71. DOI: 10.14412/1995-4484-2014-56-71Reshetnyak TM. Antiphospholipid syndrome: Diagnosis and clinical manifestations. (Lecture). Nauchno-Prakticheskaya Revmatologia = Rheumatology Science and Practice. 2014;52(1):56-71 (In Russ.). DOI: 10.14412/1995-4484-2014-56-71Garcia D, Erkan D. Diagnosis and management of the antiphospholipid syndrome. N Engl J Med. 2018;378(21):2010-2021. DOI: 10.1056/NEJMra1705454Garcia D, Erkan D. Diagnosis and management of the antiphospholipid syndrome. N Engl J Med. 2018;378(21):2010-2021. DOI: 10.1056/NEJMra1705454Miyakis S, Lockshin MD, Atsumi T, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost. 2006;4(2):295-306. DOI: 10.1111/j.1538-7836.2006.01753.xMiyakis S, Lockshin MD, Atsumi T, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost. 2006;4(2):295-306. DOI: 10.1111/j.1538-7836.2006.01753.xPengo V, Ruffatti A, Legnani C, et al. Clinical course of high risk patients diagnosed with antiphospholipid syndrome. J Thromb Haemost. 2010;8(2):237-242. DOI: 10.1111/j.1538-7836.2009.03674.xPengo V, Ruffatti A, Legnani C, et al. Clinical course of high risk patients diagnosed with antiphospholipid syndrome. J Thromb Haemost. 2010;8(2):237-242. DOI: 10.1111/j.1538-7836.2009.03674.xVolkov I, Seguro L, Leon EP, et al. Profiles of criteria and noncriteria anti-phospholipid autoantibodies are associated with clinical phenotypes of the antiphospholipid syndrome. Auto Immun Highlights. 2020;11(1):8. DOI: 10.1186/s13317-020-00131-3Volkov I, Seguro L, Leon EP, et al. Profiles of criteria and noncriteria anti-phospholipid autoantibodies are associated with clinical phenotypes of the antiphospholipid syndrome. Auto Immun Highlights. 2020;11(1):8. DOI: 10.1186/s13317-020-00131-3Tektonidou MG., Andreoli L, Limper M, et al. EULAR recommendations for the management of antiphospholipid syndrome in adults. Ann Rheum Dis. 2019;78(10):1296-1304. DOI: 10.1136/annrheumdis-2019-215213Tektonidou MG., Andreoli L, Limper M, et al. EULAR recommendations for the management of antiphospholipid syndrome in adults. Ann Rheum Dis. 2019;78(10):1296-1304. DOI: 10.1136/annrheumdis-2019-215213Kearon C, Parpia S, Spencer FA, et al. Antiphospholipid antibodies and recurrent thrombosis after a first unprovoked venous thromboembolism. Blood. 2018;131(19):2151-2160. DOI: 10.1182/blood-2017-09-805689Kearon C, Parpia S, Spencer FA, et al. Antiphospholipid antibodies and recurrent thrombosis after a first unprovoked venous thromboembolism. Blood. 2018;131(19):2151-2160. DOI: 10.1182/blood-2017-09-805689Taraborelli M, Reggia R, Dall’Ara F, et al. Long-term outcome of patients with primary antiphospholipid syndrome: A retrospective multicenter study. J Rheumatol. 2017;44(8):1165-1172. DOI: 10.3899/jrheum.161364Taraborelli M, Reggia R, Dall’Ara F, et al. Long-term outcome of patients with primary antiphospholipid syndrome: A retrospective multicenter study. J Rheumatol. 2017;44(8):1165-1172. DOI: 10.3899/jrheum.161364Tincani A, Andreoli L, Casu C, Cattaneo R, Meroni P. Antiphospholipid antibody profile: implications for the evaluation and management of patients. Lupus. 2010;19(4):432-435. DOI: 10.1177/0961203310361491Tincani A, Andreoli L, Casu C, Cattaneo R, Meroni P. Antiphospholipid antibody profile: implications for the evaluation and management of patients. Lupus. 2010;19(4):432-435. DOI: 10.1177/0961203310361491Pengo V, Ruffatti A, Legnani C, et al. Incidence of a first thromboembolic event in asymptomatic carriers of high-risk antiphospholipid antibody profile: A multicenter prospective study. Blood. 2011;118(17):4714-4718. DOI: 10.1182/blood-2011-03-340232Pengo V, Ruffatti A, Legnani C, et al. Incidence of a first thromboembolic event in asymptomatic carriers of high-risk antiphospholipid antibody profile: A multicenter prospective study. Blood. 2011;118(17):4714-4718. DOI: 10.1182/blood-2011-03-340232Asherson RA. New subsets of the antiphospholipid syndrome in 2006: “PRE-APS” (probable APS) and microangiopathic antiphospholipid syndromes (“MAPS”). Autoimmun Rev. 2006;6(2):76-80. DOI: 10.1016/j.autrev.2006.06.008Asherson RA. New subsets of the antiphospholipid syndrome in 2006: “PRE-APS” (probable APS) and microangiopathic antiphospholipid syndromes (“MAPS”). Autoimmun Rev. 2006;6(2):76-80. DOI: 10.1016/j.autrev.2006.06.008Jackson WG, Oromendia C, Unlu O, et al. Antiphospholipid syndrome alliance for clinical trials and international networking. Recurrent thrombosis in patients with antiphospholipid antibodies and arterial thrombosis on antithrombotic therapy. Blood Adv. 2017;1(25):2320-2324. DOI: 10.1182/bloodadvances.2017008185Jackson WG, Oromendia C, Unlu O, et al. Antiphospholipid syndrome alliance for clinical trials and international networking. Recurrent thrombosis in patients with antiphospholipid antibodies and arterial thrombosis on antithrombotic therapy. Blood Adv. 2017;1(25):2320-2324. DOI: 10.1182/bloodadvances.2017008185Cervera R, Serrano R, Pons-Estel GJ, et al. Morbidity and mortality in the antiphospholipid syndrome during a 10-year period: A multicentre prospective study of 1000 patients. Ann Rheum Dis. 2015;74(6):1011-1018. DOI: 10.1136/annrheumdis-2013-204838Cervera R, Serrano R, Pons-Estel GJ, et al. Morbidity and mortality in the antiphospholipid syndrome during a 10-year period: A multicentre prospective study of 1000 patients. Ann Rheum Dis. 2015;74(6):1011-1018. DOI: 10.1136/annrheumdis-2013-204838Кондратьева ЛВ, Решетняк ТМ. Профилактика тромбозов при антифосфолипидном синдроме. Современная ревматология. 2009;3(3):18-22. DOI: 10.14412/1996-7012-2009-552Kondratyeva LV, Reshetnyak TM. Prevention of thromboses in antiphospholipid syndrome. Sovremennaya Rheumatologia = Modern Rheumatology Journal. 2009;3(3):18-22 (In Russ.). DOI: 10.14412/1996-7012-2009-552Martinelli I, Abbattista M, Bucciarelli P, et al Recurrent thrombosis in patients with antiphospholipid antibodies treated with vitamin K antagonists or rivaroxaban. Haematologica. 2018;103(7):e315-e317. DOI: 10.3324/haematol.2017.185132Martinelli I, Abbattista M, Bucciarelli P, et al Recurrent thrombosis in patients with antiphospholipid antibodies treated with vitamin K antagonists or rivaroxaban. Haematologica. 2018;103(7):e315-e317. DOI: 10.3324/haematol.2017.185132Сатыбалдыева МА, Решетняк ТМ. Новые оральные антикоагулянты в терапии антифосфолипидного синдрома. Научно-практическая ревматология. 2016;54(2):219-226. doi: 10.14412/1995-4484-2016-219-226Satybaldyeva MA, Reshetnyak TM. New oral anticoagulants in the therapy of antiphospholipid syndrome. Nauchno-Prakticheskaya Revmatologia = Rheumatology Science and Practice. 2016;54(2):219-226 (In Russ.). doi: 10.14412/1995-4484-2016-219-226Hlavacek P, Guo JD, Rosenblatt L, et al. Safety, effectiveness, and health care cost comparisons among elderly patients with venous thromboembolism prescribed warfarin or apixaban in the United States Medicare population. Curr Med Res Opin. 2019;35(12):2043-2051. DOI: 10.1080/03007995.2019.1653067Hlavacek P, Guo JD, Rosenblatt L, et al. Safety, effectiveness, and health care cost comparisons among elderly patients with venous thromboembolism prescribed warfarin or apixaban in the United States Medicare population. Curr Med Res Opin. 2019;35(12):2043-2051. DOI: 10.1080/03007995.2019.1653067Chen A, Stecker E, Warden BA. Direct oral anticoagulant use: A practical guide to common clinical challenges. J Am Heart Assoc. 2020;9(13):e017559. DOI: 10.1161/JAHA.120.017559Chen A, Stecker E, Warden BA. Direct oral anticoagulant use: A practical guide to common clinical challenges. J Am Heart Assoc. 2020;9(13):e017559. DOI: 10.1161/JAHA.120.017559Ageno W, Gallus AS, Wittkowsky A, et al. Oral anticoagulant therapy: Antithrombotic therapy and prevention of thrombosis. 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141(2 Suppl):e44S-e88S. DOI: 10.1378/chest.11-2292Ageno W, Gallus AS, Wittkowsky A, et al. Oral anticoagulant therapy: Antithrombotic therapy and prevention of thrombosis. 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141(2 Suppl):e44S-e88S. DOI: 10.1378/chest.11-2292Almarshad F, Alaklabi A, Bakhsh E, Pathan A, Imegren M. Use of direct oral anticoagulants in daily practice. Am J Blood Res. 2018;8(4):57-72. DOI: 10.1097/MBC.0000000000000247Almarshad F, Alaklabi A, Bakhsh E, Pathan A, Imegren M. Use of direct oral anticoagulants in daily practice. Am J Blood Res. 2018;8(4):57-72. DOI: 10.1097/MBC.0000000000000247Undas A, Goialczyk T. Direct oral anticoagulants in patients with thrombophilia: Challenges in diagnostic evaluation and treatment. Adv Clin Exp Med. 2016;25(6):1321-1330. DOI: 10.17219/acem/65853Undas A, Goialczyk T. Direct oral anticoagulants in patients with thrombophilia: Challenges in diagnostic evaluation and treatment. Adv Clin Exp Med. 2016;25(6):1321-1330. DOI: 10.17219/acem/65853Cohen H, Hunt BJ, Efthymiou M, et al. RAPS trial investigators. Rivaroxaban versus warfarin to treat patients with thrombotic antiphospholipid syndrome, with or without systemic lupus erythematosus (RAPS): A randomised, controlled, open-label, phase 2/3, non-inferiority trial. Lancet Haematol. 2016;3(9):e426-e436. DOI: 10.1016/S2352-3026(16)30079-5Cohen H, Hunt BJ, Efthymiou M, et al. RAPS trial investigators. Rivaroxaban versus warfarin to treat patients with thrombotic antiphospholipid syndrome, with or without systemic lupus erythematosus (RAPS): A randomised, controlled, open-label, phase 2/3, non-inferiority trial. Lancet Haematol. 2016;3(9):e426-e436. DOI: 10.1016/S2352-3026(16)30079-5Alberio L. The new direct oral anticoagulants in special indications. Rationale and preliminary data in cancer, mechanical heart valves, APS, HIT, and beyond. Semin Hematol. 2014;51(2):152-156. DOI: 10.1053/j.seminhematol.2014.03.002Alberio L. The new direct oral anticoagulants in special indications. Rationale and preliminary data in cancer, mechanical heart valves, APS, HIT, and beyond. Semin Hematol. 2014;51(2):152-156. DOI: 10.1053/j.seminhematol.2014.03.002Arachchillage DR, Mackie IJ, Efthymiou M, et al. Rivaroxaban limits complement activation compared with warfarin in antiphospholipid syndrome patients with venous thromboembolism. J Thromb Haemost. 2016;14(11):2177-2186. DOI: 10.1111/jth.13475Arachchillage DR, Mackie IJ, Efthymiou M, et al. Rivaroxaban limits complement activation compared with warfarin in antiphospholipid syndrome patients with venous thromboembolism. J Thromb Haemost. 2016;14(11):2177-2186. DOI: 10.1111/jth.13475Balbi GGM, Pacheco MS, Monticielo OA, et al. Antiphospholipid Syndrome Committee of the Brazilian Society of Rheumatology position statement on the use of direct oral anticoagulants (DOACs) in antiphospholipid syndrome (APS). Adv Rheumatol. 2020;60(1):29-43. DOI: 10.1186/s42358-020-00125-9Balbi GGM, Pacheco MS, Monticielo OA, et al. Antiphospholipid Syndrome Committee of the Brazilian Society of Rheumatology position statement on the use of direct oral anticoagulants (DOACs) in antiphospholipid syndrome (APS). Adv Rheumatol. 2020;60(1):29-43. DOI: 10.1186/s42358-020-00125-9Vazquez SR. Drug-drug interactions in an era of multiple anticoagulants: A focus on clinically relevant drug interactions. Blood. 2018;132(21):2230-2239. DOI: 10.1182/blood-2018-06-848747Vazquez SR. Drug-drug interactions in an era of multiple anticoagulants: A focus on clinically relevant drug interactions. Blood. 2018;132(21):2230-2239. DOI: 10.1182/blood-2018-06-848747Ordi-Ros J, Saerz-Comet L, Perez-Conesa M, et al. Rivaroxaban versus vitamin K antagonist in antiphospholipid syndrome: A randomized noninferiority trial. Ann Intern Med. 2019;171(10):685-694. DOI: 10.7326/M19-0291Ordi-Ros J, Saerz-Comet L, Perez-Conesa M, et al. Rivaroxaban versus vitamin K antagonist in antiphospholipid syndrome: A randomized noninferiority trial. Ann Intern Med. 2019;171(10):685-694. DOI: 10.7326/M19-0291Sciascia S, Breen K, Hunt BJ. Rivaroxaban use in patients with antiphospholipid syndrome and previous venous thromboembolism. Blood Coagul Fibrinolysis. 2015;26(4):476-477. DOI: 10.1097/MBC.0000000000000247Sciascia S, Breen K, Hunt BJ. Rivaroxaban use in patients with antiphospholipid syndrome and previous venous thromboembolism. Blood Coagul Fibrinolysis. 2015;26(4):476-477. DOI: 10.1097/MBC.0000000000000247Resseguier AS, Pereira B, Rieu V, et al. Direct oral anticoagulants: An alternative treatment for thrombotic antiphospholipid syndrome. Lupus. 2017;26(12):1297-1303. DOI: 10.1177/0961203317701841Resseguier AS, Pereira B, Rieu V, et al. Direct oral anticoagulants: An alternative treatment for thrombotic antiphospholipid syndrome. Lupus. 2017;26(12):1297-1303. DOI: 10.1177/0961203317701841Betancur JF, Bonilla AF, Hormaza AA, et al. Direct oral anticoagulants in antiphospholipid syndrome: A real-life case series. Lupus. 2016;25(6):658-652. DOI: 10.1177/0961203315624555Betancur JF, Bonilla AF, Hormaza AA, et al. Direct oral anticoagulants in antiphospholipid syndrome: A real-life case series. Lupus. 2016;25(6):658-652. DOI: 10.1177/0961203315624555Hatadyj E, Olesinska M. Rivaroxaban - a safe therapeutic option in patients with antiphospholipid syndrome? Our experience in 23 cases. Reumatologia. 2016;54(3):146-149. DOI: 10.5114/reum.2016.61217Hatadyj E, Olesinska M. Rivaroxaban - a safe therapeutic option in patients with antiphospholipid syndrome? Our experience in 23 cases. Reumatologia. 2016;54(3):146-149. DOI: 10.5114/reum.2016.61217Noel N, Dutasta F, Costedoat-Chalumeau N, et al. Safety and efficacy of oral direct inhibitors of thrombin and factor Xa in antiphospholipid syndrome. Autoimmun Rev. 2015;14(8):680-685. DOI: 10.1016/j.autrev.2015.03.007Noel N, Dutasta F, Costedoat-Chalumeau N, et al. Safety and efficacy of oral direct inhibitors of thrombin and factor Xa in antiphospholipid syndrome. Autoimmun Rev. 2015;14(8):680-685. DOI: 10.1016/j.autrev.2015.03.007Malec K, Goralczyk T, Undas A. The use of direct oral anticoagulants in 56 patients with antiphospholipid syndrome. Thromb Res. 2017;152:93-97. DOI: 10.1016/j.thromres.2016.12.009Malec K, Goralczyk T, Undas A. The use of direct oral anticoagulants in 56 patients with antiphospholipid syndrome. Thromb Res. 2017;152:93-97. DOI: 10.1016/j.thromres.2016.12.009Kunk PR, Brown J, McShane M, et al. Direct oral anticoagulants in hypercoagulable states. J Thromb Thrombolysis. 2017;43(1):79-85. DOI: 10.1007/s11239-016-1420-xKunk PR, Brown J, McShane M, et al. Direct oral anticoagulants in hypercoagulable states. J Thromb Thrombolysis. 2017;43(1):79-85. DOI: 10.1007/s11239-016-1420-xSignorelli F, Nogueira F, Domingues V, et al. Thrombotic events in patients with antiphospholipid syndrome treated with rivaroxaban: A series of eight cases. Clin Rheumatol. 2016;35(3):801-805. DOI: 10.1007/s10067-015-3030-ySignorelli F, Nogueira F, Domingues V, et al. Thrombotic events in patients with antiphospholipid syndrome treated with rivaroxaban: A series of eight cases. Clin Rheumatol. 2016;35(3):801-805. DOI: 10.1007/s10067-015-3030-ySchaefer JK, Mcbane RD, Black DF, et al. Failure of dabigatran and rivaroxaban to prevent thromboembolism in antiphospholipid syndrome: A case series of three patients. Thromb Haemost. 2014;112(5):947-950. DOI: 10.1160/TH14-03-0272Schaefer JK, Mcbane RD, Black DF, et al. Failure of dabigatran and rivaroxaban to prevent thromboembolism in antiphospholipid syndrome: A case series of three patients. Thromb Haemost. 2014;112(5):947-950. DOI: 10.1160/TH14-03-0272Win K, Rodgers GM. New oral anticoagulants may not be effective to prevent venous thromboembolism in patients with antiphospholipid syndrome. Am J Hematol. 2014;89(10):1017. DOI: 10.1002/ajh.23797Win K, Rodgers GM. New oral anticoagulants may not be effective to prevent venous thromboembolism in patients with antiphospholipid syndrome. Am J Hematol. 2014;89(10):1017. DOI: 10.1002/ajh.23797Pengo V, Denas G, Zoppellaro G, et al. Rivaroxaban vs warfarin in high-risk patient with antiphospholipid syndrome. Blood. 2018;132(13):1365-1371. DOI: 10.1182/blood-2018-04-848333Pengo V, Denas G, Zoppellaro G, et al. Rivaroxaban vs warfarin in high-risk patient with antiphospholipid syndrome. Blood. 2018;132(13):1365-1371. DOI: 10.1182/blood-2018-04-848333Cortes-Hernandez J, S;iez Comet L, Perez-Conesa M, et al. Rivaroxaban versus warfarin as secondary thromboprophylaxis in patients with antiphospholipid syndrome protocol: a randomized, multicenter, open-label, clinical trial. Ann Intern Med. 2019;171(10):685-694. DOI: 10.7326/M19-0291Cortes-Hernandez J, S;iez Comet L, Perez-Conesa M, et al. Rivaroxaban versus warfarin as secondary thromboprophylaxis in patients with antiphospholipid syndrome protocol: a randomized, multicenter, open-label, clinical trial. Ann Intern Med. 2019;171(10):685-694. DOI: 10.7326/M19-0291Schulman S, Kearon C, Kakkar AK, et al. Extended use of dabiga-tran, warfarin, or placebo in venous thromboembolism. N Engl J Med. 2013;368(8):709-718. DOI: 10.1056/NEJMoa1113697Schulman S, Kearon C, Kakkar AK, et al. Extended use of dabiga-tran, warfarin, or placebo in venous thromboembolism. N Engl J Med. 2013;368(8):709-718. DOI: 10.1056/NEJMoa1113697Schulman S, Kakkar AK, Goldhaber SZ, et al. Treatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysis. Circulation. 2014;129(7):764-772. DOI: 10.1161/CIRCULATIONAHA.113.004450Schulman S, Kakkar AK, Goldhaber SZ, et al. Treatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysis. Circulation. 2014;129(7):764-772. DOI: 10.1161/CIRCULATIONAHA.113.004450Woller SC, Stevens SM, Kaplan DA, Rondina MT. Protocol modification of apixaban for the secondary prevention of thrombosis among patients with antiphospholipid syndrome study (Letter to editor). Clin Appl Thromb Hemost. 2016;22(3):239-247. DOI: 10.1177/1076029615615960Woller SC, Stevens SM, Kaplan DA, Rondina MT. Protocol modification of apixaban for the secondary prevention of thrombosis among patients with antiphospholipid syndrome study (Letter to editor). Clin Appl Thromb Hemost. 2016;22(3):239-247. DOI: 10.1177/1076029615615960ISRCTN10280992. Rivaroxaban for stroke patients with antiphospholipid syndrome. DOI: 10.1186/ISRCTN10280992ISRCTN10280992. Rivaroxaban for stroke patients with antiphospholipid syndrome. DOI: 10.1186/ISRCTN10280992Dufrost V, Risse J, Reshetnyak T, et al. Increased risk of thrombosis in antiphospholipid syndrome patients treated with direct oral anticoagulants. Results from an international patient-level data meta-analysis. Autoimmun Rev. 2018;17(10):1011-1021. DOI: 10.1016/j.autrev.2018.04.0Dufrost V, Risse J, Reshetnyak T, et al. Increased risk of thrombosis in antiphospholipid syndrome patients treated with direct oral anticoagulants. Results from an international patient-level data meta-analysis. Autoimmun Rev. 2018;17(10):1011-1021. DOI: 10.1016/j.autrev.2018.04.0Sanchez-Redondo J, Espinosa G, Varillas DD, Cervera R. Recurrent thrombosis with direct oral anticoagulants in antiphospholipid syndrome: A systematic literature review and meta-analy-sis. Clin Ther. 2019;41(9):1839-1862. DOI: 10.1016/j.clin-thera.2019.06.015Sanchez-Redondo J, Espinosa G, Varillas DD, Cervera R. Recurrent thrombosis with direct oral anticoagulants in antiphospholipid syndrome: A systematic literature review and meta-analy-sis. Clin Ther. 2019;41(9):1839-1862. DOI: 10.1016/j.clin-thera.2019.06.015Elsebaie MAT, van Es N, Langston A, Buller HR, Gaddh M. Direct oral anticoagulants in patients with venous thromboembolism and thrombophilia: A systematic review and met analysis. J Thromb. Haemost. 2019;17(4):645-656. DOI: 10.1111/jth.14398Elsebaie MAT, van Es N, Langston A, Buller HR, Gaddh M. Direct oral anticoagulants in patients with venous thromboembolism and thrombophilia: A systematic review and met analysis. J Thromb. Haemost. 2019;17(4):645-656. DOI: 10.1111/jth.14398Dufrost V, Wahl D, Zuily S. Direct oral anticoagulants in antiphospholipid syndrome: Meta-analysis of randomized controlled trials. Autoimmun Rev. 2020;Nov 13:102711. DOI: 10.1016/j.autrev.2020.102711Dufrost V, Wahl D, Zuily S. Direct oral anticoagulants in antiphospholipid syndrome: Meta-analysis of randomized controlled trials. Autoimmun Rev. 2020;Nov 13:102711. DOI: 10.1016/j.autrev.2020.102711Cerda P, Becattini C, Iriarte A, et al. Direct oral anticoagulants versus vitamin K antagonists in antiphospholipid syndrome: A meta-analysis. Eur J Intern Med. 2020;79:43-50. DOI: 10.1016/j.ejim.2020.05.012Cerda P, Becattini C, Iriarte A, et al. Direct oral anticoagulants versus vitamin K antagonists in antiphospholipid syndrome: A meta-analysis. Eur J Intern Med. 2020;79:43-50. DOI: 10.1016/j.ejim.2020.05.012Satybaldyeva MA, Seredavkina NV, Nasonov EL, Lila AM, Reshetnyak TM. Dabigatran for failed warfarin treatment in high-risk patients with antiphospholipid syndrome. ISTH 2019 Final program. 2019; PB 1097. URL: https://academy.isth.org/isth/2019/melbourne/264291/nataliya.seredavkina.dabigatran.for.failed.warfarin.treatment.in.high-risk.html?f=listing%3D0%2Abrowseby%3D8%2Asortby%3D1%2Asearch%3D-Dabigatran+for+failed+warfarin+treatment+in+high-risk+patients+with+antiphospholipid+syndrome (Date accessed: 2020).Satybaldyeva MA, Seredavkina NV, Nasonov EL, Lila AM, Reshetnyak TM. Dabigatran for failed warfarin treatment in high-risk patients with antiphospholipid syndrome. ISTH 2019 Final program. 2019; PB 1097. URL: https://academy.isth.org/isth/2019/melbourne/264291/nataliya.seredavkina.dabigatran.for.failed.warfarin.treatment.in.high-risk.html?f=listing%3D0%2Abrowseby%3D8%2Asortby%3D1%2Asearch%3D-Dabigatran+for+failed+warfarin+treatment+in+high-risk+patients+with+antiphospholipid+syndrome (Date accessed: 2020).Bala MM, Celinska-Lowenho M, Szot W, Padjas A, et al. Antiplatelet and anticoagulant agents for secondary prevention of stroke and other thromboembolic events in people with antiphospholipid syndrome. Cochrane Database Syst Rev. 2020;10:CD012169. DOI: 10.1002/14651858.CD012169.pub3Bala MM, Celinska-Lowenho M, Szot W, Padjas A, et al. Antiplatelet and anticoagulant agents for secondary prevention of stroke and other thromboembolic events in people with antiphospholipid syndrome. Cochrane Database Syst Rev. 2020;10:CD012169. DOI: 10.1002/14651858.CD012169.pub3European Medicines Agency (EMA). PRAC recommendations on signals. 2019 May 6; URL: https://www.ema.europa.eu/en/docu-ments/prac-recommendation/prac-recommendations-signals-ad-opted-8-11-april-2019-prac-meeting_en.pdf (Date accessed: 2020).European Medicines Agency (EMA). PRAC recommendations on signals. 2019 May 6; URL: https://www.ema.europa.eu/en/docu-ments/prac-recommendation/prac-recommendations-signals-ad-opted-8-11-april-2019-prac-meeting_en.pdf (Date accessed: 2020).Medicines and Healthcare products Regulatory Agency. Direct-acting oral anticoagulants (DOACs): Increased risk of recurrent thrombotic events in patients with antiphospholipid syndrome. URL: https://www.gov.uk/drug-safety-update/direct-act-ing-oral-anticoagulants-doacs-increased-risk-of-recurrent-throm-botic-events-in-patients-with-antiphospholipid-syndrome (Date accessed: 2020).Medicines and Healthcare products Regulatory Agency. Direct-acting oral anticoagulants (DOACs): Increased risk of recurrent thrombotic events in patients with antiphospholipid syndrome. URL: https://www.gov.uk/drug-safety-update/direct-act-ing-oral-anticoagulants-doacs-increased-risk-of-recurrent-throm-botic-events-in-patients-with-antiphospholipid-syndrome (Date accessed: 2020).Arachchillage DRJ, Gomez K, Alikhan R, et al. Addendum to British Society for Haematology Guidelines on Investigation and Management of Antiphospholipid syndrome, 2012 (Br. J. Haematol. 2012; 157: 47-58): Use of direct acting oral anticoagulants. Br J Haematol. 2020;189(2):212-215. DOI: 10.1111/bjh.16308.Arachchillage DRJ, Gomez K, Alikhan R, et al. Addendum to British Society for Haematology Guidelines on Investigation and Management of Antiphospholipid syndrome, 2012 (Br. J. Haematol. 2012; 157: 47-58): Use of direct acting oral anticoagulants. Br J Haematol. 2020;189(2):212-215. DOI: 10.1111/bjh.16308.Konstantinides SV, Meyer G, Becattini C, et al. 2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS). Eur Heart J. 2020;41(4):543-603. DOI: 10.1093/eurheartj/ehz405Konstantinides SV, Meyer G, Becattini C, et al. 2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS). Eur Heart J. 2020;41(4):543-603. DOI: 10.1093/eurheartj/ehz405Agence Nationale de Securite du Medicaments (ANSM). Anticoagulants Oraux Directs (AODs) (apixaban (Eliquis®), rivaroxaban (Xarelto®), dabigatran (Pradaxa®) et edoxaban (Lixiana®/ Roteas®) non recommandes chez les patients presentant un Syndrome des Antiphospholipides (SAPL) - Lettre aux profession-nels de sante. 2019 May 24. URL: https://ansm.sante.fr/S-informer/Informations-de-securite-Lettres-aux-professionnels-de-sante/Anticoagulants-Oraux-Directs-AODs-apixaban-Eliquis-R-rivaroxaban-Xarelto-R-dabigatran-Pradaxa-R-et-edoxaban-Lix-iana-R-Roteas-R-non-recommandes-chez-les-patients-presentant-un-Syndrome-des-Antiphospholipides-SAPL-Lettre-aux-profes-sionnels-de-sante (Date accessed: 2020).Agence Nationale de Securite du Medicaments (ANSM). Anticoagulants Oraux Directs (AODs) (apixaban (Eliquis®), rivaroxaban (Xarelto®), dabigatran (Pradaxa®) et edoxaban (Lixiana®/ Roteas®) non recommandes chez les patients presentant un Syndrome des Antiphospholipides (SAPL) - Lettre aux profession-nels de sante. 2019 May 24. URL: https://ansm.sante.fr/S-informer/Informations-de-securite-Lettres-aux-professionnels-de-sante/Anticoagulants-Oraux-Directs-AODs-apixaban-Eliquis-R-rivaroxaban-Xarelto-R-dabigatran-Pradaxa-R-et-edoxaban-Lix-iana-R-Roteas-R-non-recommandes-chez-les-patients-presentant-un-Syndrome-des-Antiphospholipides-SAPL-Lettre-aux-profes-sionnels-de-sante (Date accessed: 2020).Bauersachs R, Langer F, Kalka C, et al. Treatment of the antiphospholipid syndrome with direct oral anticoagulants: Position statement of German societies. Vasa. 2019;48(6):483-486. DOI: 10.1024/0301-1526/a000815Bauersachs R, Langer F, Kalka C, et al. Treatment of the antiphospholipid syndrome with direct oral anticoagulants: Position statement of German societies. Vasa. 2019;48(6):483-486. DOI: 10.1024/0301-1526/a000815Zuily S, Cohen H, Isenberg D, et al. Use of direct oral anticoagulants in patients with thrombotic antiphospholipid syndrome: Guidance from the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. J Thromb Haemost. 2020;18(9):2126-2137. DOI: 10.1111/jth.1Zuily S, Cohen H, Isenberg D, et al. Use of direct oral anticoagulants in patients with thrombotic antiphospholipid syndrome: Guidance from the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. J Thromb Haemost. 2020;18(9):2126-2137. DOI: 10.1111/jth.1

The authors declare that there are no conflicts of interest present.